---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-065400"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:41:49.559126+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal partners with Abbott for pivotal tecarfarin trial in LVAD patients

## Summary
- Cadrenal (CVKD) and Abbott (ABT) initiate collaborative effort for tecarfarin pivotal trial in recently implanted LVAD patients.
- Tecarfarin received FDA Orphan Drug Designation in April 2024 for preventing clots in mechanical circulatory support devices.
- Only LVAD available in U.S. is Abbott's HeartMate 3; collaboration aims to improve anticoagulation outcomes.
- Prior clinical data suggest tecarfarin yields better anticoagulation quality in LVAD-relevant populations (multiple meds, renal impairment).

## SEC filing metadata
- accession: 0001213900-24-065400
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024065400/0001213900-24-065400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024065400/ea0210607-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-065400
- JSON: https://secwatch.observer/filing/0001213900-24-065400.json
- Plain text: https://secwatch.observer/filing/0001213900-24-065400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.